YD Bio director Kochi Chang receives 3,135 shares

Each quarterly vesting amount is determined by dividing $15,000 by the seven-trading-day volume-weighted average price before vesting.

Rhea-AI Filing Summary

YD Bio Ltd (symbol: YDES) is the issuer of record for a Form 4 filing submitted to the SEC. YD Bio Ltd director Kochi Chang acquired 3,135 restricted share units upon vesting on September 30, 2026; the units converted into 3,135 ordinary shares, and the reported direct ordinary-share position after the transaction was 10,965 shares. The RSUs were granted under the YD Bio Limited Equity Incentive Plan on March 31, 2026, with an aggregate target grant date fair value of $60,000, and vest in four equal quarterly installments.

Insider Trade Summary

3,135 shares exercised/converted

Exercise 3 txns

Insider Chang Kochi

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Share Units F1, F2, F3	3,135	$0.00	$0.00
Exercise	Restricted Share Units F1, F2	3,135	$0.00	$0.00
Exercise	Ordinary Shares F1	3,135	--	--

Holdings After Transaction: Restricted Share Units — 0 contracts (Direct); Ordinary Shares — 10,965 shares (Direct)

Footnotes (3)

1. F1. Each restricted share unit ("RSU") represents a contingent right to receive one ordinary share, par value $0.0001 per share ("Ordinary Shares"), of YD Bio Limited.
2. F2. The RSUs were granted pursuant to the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000 on March 31, 2026 (the "Granted RSUs"). The Granted RSUs vest in four equal quarterly installments beginning March 31, 2026, with the number of RSUs subject to vesting to be determined on the applicable vesting date by dividing $15,000 by the seven (7) trading-day volume-weighted average price of the Company's Ordinary Shares ending on the trading day immediately prior to such vesting.
3. F3. The Reporting Person became entitled to a fixed number of RSUs on September 30, 2026 (the "Vesting Date").

Key Figures

Restricted share units acquired: 3,135 units Ordinary shares acquired: 3,135 shares Direct ordinary shares following transaction: 10,965 shares +4 more

7 metrics

Restricted share units acquired 3,135 units Vesting on September 30, 2026

Ordinary shares acquired 3,135 shares Converted from restricted share units on September 30, 2026

Direct ordinary shares following transaction 10,965 shares Reported after the September 30, 2026 transaction

Aggregate target grant date fair value $60,000 RSUs granted March 31, 2026

Quarterly vesting amount used in formula $15,000 Divided by the seven-trading-day volume-weighted average price

Vesting installments 4 installments Equal quarterly installments

Ordinary shares represented by each RSU 1 ordinary share Each restricted share unit represents a contingent right to receive one ordinary share

Key Terms

restricted share unit, volume-weighted average price, grant date fair value, contingent right

4 terms

restricted share unit financial

"Each restricted share unit ("RSU") represents a contingent right"

A restricted share unit (RSU) is a promise by a company to give an employee a set number of company shares at a future date, typically after meeting time or performance conditions. For investors, RSUs matter because when they convert into actual shares they increase the number of shares outstanding (like unlocking more tickets in a game), which can dilute existing holders, and they align employee incentives with company performance, influencing behavior and long-term value.

volume-weighted average price financial

"seven (7) trading-day volume-weighted average price"

Volume-weighted average price (VWAP) is the average price of a stock over a specific time period where each trade is weighted by the number of shares traded, so larger trades influence the average more than small ones. Investors and traders use VWAP as a reference point to judge whether trades are happening at relatively good or poor prices—like checking the average price paid for an item at a market where bulk purchases count more than single-item buys.

grant date fair value financial

"aggregate target grant date fair value of $60,000"

The grant date fair value is the estimated dollar worth of a stock-based award (such as stock options or restricted shares) at the exact moment it is given to an employee or contractor. Investors care because companies use that value to record compensation expenses and to show how much potential ownership and earnings dilution those awards could create—think of it as the price tag placed on a gift card when it is handed over so the company can report the cost now.

contingent right technical

"represents a contingent right to receive one ordinary share"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many YDES shares did director Kochi Chang receive?

Kochi Chang acquired 3,135 restricted share units on September 30, 2026, and they converted into 3,135 ordinary shares. The reported direct ordinary-share position after the transaction was 10,965 shares.

How are YDES restricted share units vested?

YD Bio's RSUs vest in four equal quarterly installments. The number vesting on each applicable date is determined by dividing $15,000 by the seven-trading-day volume-weighted average price ending on the trading day immediately before that date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/06/2026 - 04:00 PM Accepted by SEC EDGAR 10/06/2026 - 04:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chang Kochi

(Last) (First) (Middle)

C/O YD BIO LIMITED

12F., NO. 3, XINGNAN ST., NANGANG DIST.

(Street)

TAIPEI CITY TAIWAN 115001

(City) (State) (Zip)

TAIWAN

(Country)

2. Issuer Name and Ticker or Trading Symbol
YD Bio Ltd [ YDES ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	09/30/2026		M		3,135	A	(1)	10,965	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(1)	09/30/2026		A		3,135(2)(3)		(2)	(2)	Ordinary Shares	3,135	$0	3,135	D
Restricted Share Units	(1)	09/30/2026		M			3,135	(2)	(2)	Ordinary Shares	3,135	$0	0	D

Explanation of Responses:

1. Each restricted share unit ("RSU") represents a contingent right to receive one ordinary share, par value $0.0001 per share ("Ordinary Shares"), of YD Bio Limited.

2. The RSUs were granted pursuant to the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000 on March 31, 2026 (the "Granted RSUs"). The Granted RSUs vest in four equal quarterly installments beginning March 31, 2026, with the number of RSUs subject to vesting to be determined on the applicable vesting date by dividing $15,000 by the seven (7) trading-day volume-weighted average price of the Company's Ordinary Shares ending on the trading day immediately prior to such vesting.

3. The Reporting Person became entitled to a fixed number of RSUs on September 30, 2026 (the "Vesting Date").

	/s/ Kochi Chang	10/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)